Hugel's hyaluronic acid filler product wins sale approval in China
With permission from China's National Medical Products Administration, the product will be sold under the name Persnica.
Distribution will be handled by Beijing-based Sihuan Pharmaceutical.
The move comes about two years after Hugel gained approval for its Letybo botulinum toxin product in China, marking a first for a Korean company.
The hyaluronic acid filler market is rapidly growing and becoming more competitive.
The size of the Chinese hyaluronic acid filler market, which was around 950 billion won ($770 million) in 2020, is expected to grow to 1.93 trillion won in 2023, and 3 trillion won in 2025, according to Hugel.
"Hugel's hyaluronic acid filler product, recognized for its quality, has been growing fast in the global market including the European market," said a spokesperson for Hugel. "We will endeavor to make it the best filler product in China."
BY SARAH CHEA [email@example.com]